BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35255940)

  • 21. Challenges in Stratifying the Molecular Variability of Patient-Derived Colon Tumor Xenografts.
    Cybulska M; Olesinski T; Goryca K; Paczkowska K; Statkiewicz M; Kopczynski M; Grochowska A; Unrug-Bielawska K; Tyl-Bielicka A; Gajewska M; Mroz A; Dabrowska M; Karczmarski J; Paziewska A; Zając L; Bednarczyk M; Mikula M; Ostrowski J
    Biomed Res Int; 2018; 2018():2954208. PubMed ID: 30662905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine.
    Gao Y; Zhou R; Huang JF; Hu B; Cheng JW; Huang XW; Wang PX; Peng HX; Guo W; Zhou J; Fan J; Yang XR
    Front Oncol; 2021; 11():704042. PubMed ID: 34327143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
    Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
    Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits.
    Corso S; Isella C; Bellomo SE; Apicella M; Durando S; Migliore C; Ughetto S; D'Errico L; Menegon S; Moya-Rull D; Cargnelutti M; Capelôa T; Conticelli D; Giordano J; Venesio T; Balsamo A; Marchiò C; Degiuli M; Reddavid R; Fumagalli U; De Pascale S; Sgroi G; Rausa E; Baiocchi GL; Molfino S; Pietrantonio F; Morano F; Siena S; Sartore-Bianchi A; Bencivenga M; Mengardo V; Rosati R; Marrelli D; Morgagni P; Rausei S; Pallabazzer G; De Simone M; Ribero D; Marsoni S; Sottile A; Medico E; Cassoni P; Sapino A; Pectasides E; Thorner AR; Nag A; Drinan SD; Wollison BM; Bass AJ; Giordano S
    Cancer Res; 2019 Nov; 79(22):5884-5896. PubMed ID: 31585941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orthotopic Implantation Achieves Better Engraftment and Faster Growth Than Subcutaneous Implantation in Breast Cancer Patient-Derived Xenografts.
    Okano M; Oshi M; Butash A; Okano I; Saito K; Kawaguchi T; Nagahashi M; Kono K; Ohtake T; Takabe K
    J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):27-36. PubMed ID: 32109311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone.
    Oyama R; Takahashi M; Kito F; Sakumoto M; Shiozawa K; Qiao Z; Yoshida A; Endo M; Kawai A; Kondo T
    In Vitro Cell Dev Biol Anim; 2018 Jun; 54(6):458-467. PubMed ID: 29845452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.
    Wen J; Wang L; Ren J; Kranz E; Chen S; Wu D; Kanazawa T; Chen I; Lu Y; Kamata M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor.
    Sicklick JK; Leonard SY; Babicky ML; Tang CM; Mose ES; French RP; Jaquish DV; Hoh CK; Peterson M; Schwab R; Lowy AM
    J Transl Med; 2014 Feb; 12():41. PubMed ID: 24507750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
    Randall J; Evans K; Watts B; Smith CM; Hughes K; Earley EJ; Erickson SW; Pachter JA; Teicher BA; Smith MA; Lock RB
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30398. PubMed ID: 37140091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
    Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
    Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
    Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
    FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
    Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
    Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NSG mice as hosts for oncological precision medicine.
    Maletzki C; Bock S; Fruh P; Macius K; Witt A; Prall F; Linnebacher M
    Lab Invest; 2020 Jan; 100(1):27-37. PubMed ID: 31409886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of B-NDG
    Guan L; Zou Q; Liu Q; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Aug; 40(8):1200-1206. PubMed ID: 32895183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel immunodeficient rat model supports human lung cancer xenografts.
    He D; Zhang J; Wu W; Yi N; He W; Lu P; Li B; Yang N; Wang D; Xue Z; Zhang P; Fan G; Zhu X
    FASEB J; 2019 Jan; 33(1):140-150. PubMed ID: 29944447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
    Drapkin BJ; George J; Christensen CL; Mino-Kenudson M; Dries R; Sundaresan T; Phat S; Myers DT; Zhong J; Igo P; Hazar-Rethinam MH; Licausi JA; Gomez-Caraballo M; Kem M; Jani KN; Azimi R; Abedpour N; Menon R; Lakis S; Heist RS; Büttner R; Haas S; Sequist LV; Shaw AT; Wong KK; Hata AN; Toner M; Maheswaran S; Haber DA; Peifer M; Dyson N; Thomas RK; Farago AF
    Cancer Discov; 2018 May; 8(5):600-615. PubMed ID: 29483136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies.
    William D; Mullins CS; Schneider B; Orthmann A; Lamp N; Krohn M; Hoffmann A; Classen CF; Linnebacher M
    J Transl Med; 2017 Feb; 15(1):27. PubMed ID: 28183348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts.
    Swick AD; Stein AP; McCulloch TM; Hartig GK; Ong IM; Sampene E; Prabakaran PJ; Liu CZ; Kimple RJ
    Oral Oncol; 2017 Jan; 64():65-72. PubMed ID: 28024726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
    Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.